Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of December 28, 2025 [1] Core Insights - The report highlights the intensive policy support for brain-computer interface (BCI) technology development, particularly in the medical field, with several policies already implemented [2] - It emphasizes the significant market opportunity in radiation therapy equipment, particularly the ZAP-X system, which is expected to capture a substantial share of the growing market for non-invasive tumor radiation treatment [3] - The introduction of pathology fee reforms is seen as a breakthrough for the commercialization of AI applications in pathology, allowing for better integration of AI-assisted diagnostics into the pricing structure [5] - The report discusses the trend of Chinese innovative drugs entering international markets, which is expected to reduce domestic competition and provide new valuation anchors for these companies [6] - It also notes the promising developments in oral autoimmune drugs and small nucleic acid drugs, with several companies making significant progress in clinical trials [7][9] Summary by Sections 1. Policy Support for BCI Technology - In July 2025, a joint opinion was issued by multiple government departments to promote BCI industry innovation, with medical health being a core application area [2] - The National Medical Products Administration (NMPA) has prioritized the approval of implantable BCI medical devices, with expected registration certificates to be issued by Q1 2026 [2] 2. Radiation Therapy Equipment Market - The ZAP-X system is designed for precise radiation therapy for brain tumors, with a significant patient population in China, estimated at 1.5 million new cases of brain metastases annually [3] - The non-invasive tumor radiation treatment market is projected to grow from RMB 27.2 billion in 2018 to RMB 59.4 billion by 2024, with a compound annual growth rate (CAGR) of 13.9% [3] 3. AI in Pathology - The NMPA's new guidelines for pathology services include AI-assisted diagnostics as an expansion item, which will help streamline the commercialization of AI technologies in pathology [5] 4. Innovative Drug Exports - The report notes that partnerships between Chinese companies and international firms are increasing, providing funding and reducing competition in the domestic market [6] - The innovative drug index has risen by 38.11% since the beginning of 2025, outperforming the CSI 300 index [6] 5. Oral Autoimmune Drugs - Takeda's new oral TYK2 inhibitor has shown positive results in clinical trials for psoriasis, indicating a potential breakthrough in treatment options [7] - Several domestic companies are also advancing in the development of oral autoimmune drugs targeting various conditions [7] 6. Small Nucleic Acid Drugs - Yuyuan Pharmaceutical's YKYY032 injection has received clinical approval from both the FDA and NMPA, with multiple companies in China advancing in the small nucleic acid drug space [9] - The report highlights the reliability of domestic technology platforms as they progress through clinical trials [9] 7. Stock Recommendations - The report recommends specific companies based on the identified opportunities, including Meihua Medical for BCI technology, Baiyang Pharmaceutical for ZAP-X, and Yuyuan Pharmaceutical for small nucleic acid drugs [11]

Investment Rating - The report does not explicitly state an investment rating for the industry [2]. Core Insights - The pathology business is entering a fast track with the National Healthcare Security Administration issuing guidelines for pricing projects in pathology services, focusing on biopsy sampling, sample processing, and digitalization of pathology data, which is expected to enhance the application of AI in the field [3][11]. - The influenza activity has peaked across the board, with reported cases in southern provinces at 9.7%, down from 11.2% the previous week, but higher than the same period in previous years [3][11]. Market Weekly Review - The pharmaceutical and biotechnology sector fell by 0.14% from December 15 to December 19, outperforming the Wind All A index (-0.15%) and the CSI 300 index (-0.28%). The rebound was weak, with segments like pharmaceutical distribution (5.59%), offline pharmacies (4.69%), and hospitals (4.15%) leading gains, while chemical preparations (-2.1%), vaccines (-0.87%), and medical R&D outsourcing (-0.87%) lagged [3][8]. - Notable stock performances included Huaren Health (55.9%), Luyuan Pharmaceutical (36.8%), and Shuyupingmin (35.7%) with significant gains, while *ST Changyao (-24%), Yipinhong (-23.7%), and Rejing Biology (-16.5%) faced substantial declines [3][11]. Industry News and Key Company Announcements - The National Healthcare Security Administration's guidelines for pathology services are expected to drive high-quality development in the sector and create new scenarios for AI-assisted technology applications [11]. - Significant collaborations and approvals were reported, including Shanghai Jinmante's partnership with Jiangsu Kangning Jerey for a breakthrough therapy designation from the FDA for JSKN003, and Novo Nordisk's submission of a marketing application for CagriSema, which showed a weight loss of 22.7% over 68 weeks in clinical trials [12][13]. - Fosun Pharma's subsidiary received FDA approval to initiate a Phase I clinical trial for HLX18, a biosimilar to Nivolumab, targeting various cancers [13][14].

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The trend of Chinese innovative drugs going overseas is opening up long-term value for companies, with significant collaborations occurring since September 2025. The innovative drug index has decreased by 11.34% from September 1 to December 19, underperforming the CSI 300 index by 12.93 percentage points. However, the index has increased by 38.65% since the beginning of the year, outperforming the CSI 300 index by 20.76 percentage points [2] - The report emphasizes the importance of oral immunomodulatory drugs, highlighting the positive results from Takeda's TYK2 inhibitor, zasocitinib, in treating moderate to severe plaque psoriasis. This drug is expected to provide significant benefits to patients and is part of a broader trend of domestic companies developing oral immunomodulatory drugs [3] - The report notes the progress of domestic small nucleic acid drugs, with YKYY032 receiving clinical approval from both the FDA and NMPA. The report anticipates an increase in clinical approvals for small nucleic acid drugs by 2026, as more companies enter this field [5] - The report tracks the flu season, indicating a peak in flu cases and a corresponding increase in the use of new flu medications, which are expected to see significant sales growth due to improved treatment protocols and online sales [7] - The report highlights a recovery in the financing of domestic innovative drugs, with a total financing amount of $5.51 billion in the first three quarters of 2025, a 67.6% increase year-on-year. The report also notes a significant increase in orders for CXO companies, indicating a positive trend in the industry [8] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.14 percentage points in the last week, ranking 22nd among 31 sectors [20] - Over the past month, the pharmaceutical industry underperformed the CSI 300 index by 2.06 percentage points, ranking 19th [24] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index has decreased by 2.50% over the past month, underperforming the CSI 300 index by 2.06 percentage points [40] - The current PE (TTM) for the pharmaceutical industry index is 37.07, above the five-year historical average of 31.16 [44] 3. Recent Research Achievements - The report includes various deep-dive studies on the pharmaceutical industry, focusing on topics such as the growth of oral drugs and the stability of blood products [48] 4. Recent Industry Policies and News - Recent policies from the National Healthcare Security Administration aim to improve the quality and efficiency of medical insurance fund settlements, which could positively impact the pharmaceutical sector [50] - Significant news includes the approval of new drugs by various companies, indicating ongoing innovation and development within the industry [51][52]

YKYY032注射液是一款偶联N-乙酰半乳糖胺(GalNAc)配体的化学合成双链siRNA药物，通过RNA干扰 机制特异性沉默LPA基因转录的mRNA，从源头阻断脂蛋白(a)[Lp(a)]生成，拟用于高脂蛋白(a)血症治 疗。临床前研究显示，该药物在体外及体内均展现显著药理活性，在多种动物模型中可有效降低 LPAmRNA及Lp(a)蛋白水平，在非人灵长类动物中更伴随LDL-C和ApoB水平下降，呈现良好且持久的 降血脂效果，且重复给药毒性研究证实其具备良好的安全性与耐受性。 智通财经APP讯，悦康药业(688658.SH)发布公告，公司子公司北京悦康科创医药科技股份有限公司、 杭州天龙药业有限公司于近日获得国家药品监督管理局(简称"NMPA")核准签发的关于YKYY032注射液 用于治疗高脂蛋白(a)血症的《药物临床试验批准通知书》。悦康科创于近日获得美国食品药品监督管 理局(简称"FDA")关于同意YKYY032注射液用于治疗高脂蛋白(a)血症进行临床试验的函告 (StudyMayProceedLetter，IND编号：178774)。 ...

YKYY032 注射液是一款偶联 N-乙酰半乳糖胺(GalNAc)配体的化学合成双链 siRNA 药物，通过 RNA 干 扰机制特异性沉默 LPA 基因转录的mRNA，从源头阻断脂蛋白 (a) [Lp (a)] 生成，拟用于高脂蛋白 (a) 血 症治疗。临床前研究显示，该药物在体外及体内均展现显著药理活性，在多种动物模型中可有效降低 LPA mRNA 及 Lp (a) 蛋白水平，在非人灵长类动物中更伴随LDL-C和ApoB水平下降，呈现良好且持久 的降血脂效果，且重复给药毒性研究证实其具备良好的安全性与耐受性。 格隆汇12月19日丨悦康药业(688658.SH)公布,公司子公司北京悦康科创医药科技股份有限公司、杭州天 龙药业有限公司于近日获得国家药品监督管理局核准签发的关于 YKYY032 注射液用于治疗高脂蛋白(a) 血症的《药物临床试验批准通知书》。悦康科创于近日获得美国食品药品监督管理局关于同意 YKYY032 注射液用于治疗高脂蛋白(a)血症进行临床试验的函告(Study May Proceed Letter，IND 编号： 178774)。 ...

Core Viewpoint - Yuyuan Pharmaceutical announced that its subsidiaries, Beijing Yuyuan Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd., have recently received approval from the National Medical Products Administration for the clinical trial of YKYY032 injection for the treatment of hyperlipoproteinemia(a) [1] Group 1 - Yuyuan Kechuang has also received a notification from the U.S. Food and Drug Administration (FDA) granting permission to conduct clinical trials for YKYY032 injection for the treatment of hyperlipoproteinemia(a) [1]

Core Viewpoint - Yuyuan Pharmaceutical announced that its subsidiaries, Beijing Yuyuan Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd., have received approval from the National Medical Products Administration for the clinical trial of YKYY032 injection for the treatment of hyperlipoproteinemia(a) [1] Group 1 - The approval from the National Medical Products Administration includes the issuance of a "Drug Clinical Trial Approval Notice" for YKYY032 injection [1] - Yuyuan Kechuang has also received a letter of consent from the U.S. Food and Drug Administration to conduct clinical trials for YKYY032 injection for the same indication [1]

每经AI快讯，12月19日，悦康药业(688658.SH)公告称，公司子公司北京悦康科创医药科技股份有限公 司、杭州天龙药业有限公司近日获得NMPA核准签发的关于YKYY032注射液用于治疗高脂蛋白(a)血症 的《药物临床试验批准通知书》。同时，悦康科创获得FDA关于同意YKYY032注射液用于治疗高脂蛋 白(a)血症进行临床试验的函告。YKYY032注射液是一款偶联N-乙酰半乳糖胺(GalNAc)配体的化学合成 双链siRNA药物，通过RNA干扰机制特异性沉默LPA基因转录的mRNA，从源头阻断脂蛋白(a)[Lp(a)]生 成，拟用于高脂蛋白(a)血症治疗。该新药临床试验申请获NMPA及FDA批准是公司新药研发的阶段性成 果，但药品从研制到投产的周期长、环节多、风险高，对公司近期业绩不会产生重大影响。 ...